Adicet Bio (ACET) Competitors

ADMA Biologics (NASDAQ:ADMA) and Adicet Bio (NASDAQ:ACET) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Which has more risk and volatility, ADMA or ACET?

ADMA Biologics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Adicet Bio has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500.

Is ADMA or ACET more profitable?

ADMA Biologics has a net margin of 44.06% compared to Adicet Bio's net margin of 0.00%. ADMA Biologics' return on equity of 41.01% beat Adicet Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	44.06%	41.01%	28.47%
Adicet Bio	N/A	-68.48%	-57.84%

Do insiders and institutionals have more ownership in ADMA or ACET?

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 83.9% of Adicet Bio shares are held by institutional investors. 3.5% of ADMA Biologics shares are held by company insiders. Comparatively, 7.8% of Adicet Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Which has better earnings and valuation, ADMA or ACET?

ADMA Biologics has higher revenue and earnings than Adicet Bio. Adicet Bio is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$426.45M	9.63	$197.67M	$0.86	20.00
Adicet Bio	$24.99M	2.29	-$117.12M	-$1.31	-0.52

Do analysts recommend ADMA or ACET?

ADMA Biologics presently has a consensus price target of $27.67, suggesting a potential upside of 60.85%. Adicet Bio has a consensus price target of $6.00, suggesting a potential upside of 774.64%. Given Adicet Bio's higher probable upside, analysts clearly believe Adicet Bio is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
Adicet Bio	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Does the media prefer ADMA or ACET?

In the previous week, ADMA Biologics had 10 more articles in the media than Adicet Bio. MarketBeat recorded 14 mentions for ADMA Biologics and 4 mentions for Adicet Bio. ADMA Biologics' average media sentiment score of 0.68 beat Adicet Bio's score of -0.01 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	8 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adicet Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ADMA Biologics beats Adicet Bio on 11 of the 16 factors compared between the two stocks.